2
Announcements
Trials
Browse
Landscape
Status
Withdrawn
1
Sponsor Class
INDUSTRY
1
Study Type
Observational
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Lymphoid
1
Conditions
Polycystic Ovary Syndrome
3
Fatty Liver
2
Diabetes Mellitus
2
Thyroid Neoplasms
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Obesity
1
Neoplasms
1
Menstruation Disturbances
1
Lymphoma, T-Cell, Cutaneous
1
Lymphoma
1
Iron Overload
1
Hypertriglyceridemia
1
Hyperthyroidism
1
Hemoglobinopathies
1
Graves Disease
1
Glucose Metabolism Disorders
1
Glucose Intolerance
1
Fibrous Dysplasia, Polyostotic
1
Fibrous Dysplasia of Bone
1
Interventions
fludarabine
4
fludarabine phosphate
3
Thiotepa
2
Melphalan
2
Clofarabine
2
Busulfan
2
AP 1903 reagent
2
Tacrolimus
1
Photopheresis
1
Mycophenolic Acid
1
Methylprednisolone Hemisuccinate
1
Methylprednisolone
1
Glucose Tolerance Test
1
Cyclosporins
1
Cyclophosphamide
1
Continuous Glucose Monitoring
1
Clinical Trials, Phase I as Topic
1
Bone Marrow Transplantation
1
Alemtuzumab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Hemoglobinopathies
×
Glucose Tolerance Test
×
Clear all
NCT03141398
2017-07-26
CGMs
Hamad Medical Corporation
Withdrawn